Company Description: ‘Second-generation’ microbiome company developing world’s first biosynthetic, donor-independent, autonomous, bio-mimicking microbiome biotherapeutics predicted and synthesized in a deep-tech approach to decolonize Antibiotic-Resistant Bateria and prevent invasive infections, to enhance immune system to fight cancer and bone marrow transplantation/ cellular therapies complications and for longevity purposes. New drug type, new therapeutic areas, enormous market. Human Biome is one, and possibly the only one among other microbiome-oriented companies, with a full spectrum of resources to build a precise and effective donor-independent, biosynthetic and bio-mimicking microbiome drug: our own donor bank, a donor-dependent anaerobic microbiota preparation facility, a biobank, a clinical platform for proof of concept studies, and a drug discovery platform consisting of a computational platform and a deep tech laboratory with unique features on a global scale, being ultimately capable to synthesized New-z Generation Biotherapeutics (NGBs). We are developing drugs that will provide revolutionary solutions, including orphan ones, in areas of great need, such as for the decolonization of antibiotic-resistant bacteria and the prevention of drug-resistant infections. Currently at least 800 million people in the world are colonized with severely antibiotic-resistant bacteria, and there is no active therapy to get rid of them and prevent subsequent invasive, deadly infections. We educate the market and create a new market with capitalization in the tens of billions of dollars. Prevention is better than cure. And if treatment is needed, it must be precise and tailored. .